Livestream #1 Posttest/Evaluation: Keeping Abreast of the Development of Vaccines to Prevent COVID-19 - What Clinicians Need to Know (ID (ID: i786) For questions 1-3, please select which of the following currently available or emerging vaccines for COVID-19 best satisfies the criteria listed. Question Title * 1. Which vaccine has the greatest efficacy in preventing symptomatic COVID-19 after the first dose? AstraZeneca/Oxford vaccine Janssen/NIH vaccine Moderna/NIH vaccine Novavax vaccine Pfizer/BioNTech vaccine Question Title * 2. Which vaccine shows greater efficacy when the interval between doses is longer? AstraZeneca/Oxford vaccine Janssen/NIH vaccine Moderna/NIH vaccine Novavax vaccine Pfizer/BioNTech vaccine Question Title * 3. Which vaccine has a reported efficacy of 85% against severe disease and 66% against the Brazil variant (P.1)? AstraZeneca/Oxford vaccine Janssen/NIH vaccine Novavax vaccine Question Title * 4. Judy is a 74-year-old female patient with obesity, type 2 diabetes, glaucoma, and hyperlipidemia. She has serious allergies to shellfish and tree nuts and possibly a few medications but she’s unsure. She retired from teaching several years ago and no longer drives due to her poor vision and difficulty moving around safely. She doesn’t really like needles and has skipped a few flu shots in the past because of it. Because her family wants the best for her, she inquires today about getting vaccinated for COVID-19. Which of the following may be most true for Judy? Judy should ask for the vaccine with the highest reported efficacy Judy’s doctor may want her to avoid vaccines with reported anaphylactic reactions Judy should not be vaccinated because she is in a high-risk group for serious adverse events from vaccination Judy does not need to be vaccinated because all of her family and close friends have been already Question Title * 5. What is your degree? MD/DO NP PA Pharmacist Nurse Other (please specify) Question Title * 6. What is your specialty? Infectious disease Immunology Geriatric medicine Internal medicine Family practice/Primary care Other (please specify) Question Title * 7. Please select the option that best describes your practice setting. Academic medical center Community medical center Question Title * 8. How many years have you been in practice? <1 1-10 11-20 >21 Question Title * 9. How many of your patients ask you for information on the COVID-19 vaccines? Few, if any Many - at least half Most, if not all Question Title * 10. Following your participation in this activity, how confident are you in providing information about COVID-19 vaccines to your patients? Very confident Confident Neutral Little confidence No confidence Question Title * 11. Which new strategies/skills/information will you apply to your area of practice? Please select all that apply. Increased knowledge of safety of vaccines undergoing late-stage development for COVID-19 Increased knowledge of general efficacy of vaccines undergoing late-stage development for COVID-19 Better understanding of available data on efficacy of vaccines against specific variant strains of COVID-19 Improved ability to identify patients for vaccination based on available data Question Title * 12. How committed are you to making changes in your practice based on your participation in this activity? Very committed Committed Neutral Not committed I do not plan to make changes If not committed or do not plan to make changes, please indicate reason Question Title * 13. What barriers do you see to making changes in your practice? Please select all that apply. Lack of knowledge regarding evidence-based strategies Lack of convincing evidence to warrant change Lack of time/resources to consider change Insurance, reimbursement or legal issues Conflicting guidelines or evidence Patient compliance and/or patient resource barriers Other Question Title * 14. After participating in today’s activity, I am now better able to: Strongly agree Agree Neutral Disagree Strongly disagree Report on vaccine candidates for COVID-19 that are in late-stages of development, including safety and efficacy data and prescribing considerations Report on vaccine candidates for COVID-19 that are in late-stages of development, including safety and efficacy data and prescribing considerations Strongly agree Report on vaccine candidates for COVID-19 that are in late-stages of development, including safety and efficacy data and prescribing considerations Agree Report on vaccine candidates for COVID-19 that are in late-stages of development, including safety and efficacy data and prescribing considerations Neutral Report on vaccine candidates for COVID-19 that are in late-stages of development, including safety and efficacy data and prescribing considerations Disagree Report on vaccine candidates for COVID-19 that are in late-stages of development, including safety and efficacy data and prescribing considerations Strongly disagree Question Title * 15. Please rate your level of agreement by checking the appropriate rating. Strongly agree Agree Neutral Disagree Strongly disagree Faculty for this activity was effective Faculty for this activity was effective Strongly agree Faculty for this activity was effective Agree Faculty for this activity was effective Neutral Faculty for this activity was effective Disagree Faculty for this activity was effective Strongly disagree Content was scientifically rigorous and evidence based Content was scientifically rigorous and evidence based Strongly agree Content was scientifically rigorous and evidence based Agree Content was scientifically rigorous and evidence based Neutral Content was scientifically rigorous and evidence based Disagree Content was scientifically rigorous and evidence based Strongly disagree Avoided commercial bias or influence Avoided commercial bias or influence Strongly agree Avoided commercial bias or influence Agree Avoided commercial bias or influence Neutral Avoided commercial bias or influence Disagree Avoided commercial bias or influence Strongly disagree Question Title * 16. If you indicated that you perceived commercial bias or influence, please describe: Question Title * 17. As a result of your participation in this activity, what is the one change you are most likely to implement in your practice? Question Title * 18. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities: Question Title * 19. Request for CME Credit: I participated in the entire activity and claim 1.25 credit(s). I participated in only part of the activity and claim 1.0 credit(s). I participated in only part of the activity and claim 0.75 credit(s). I participated in only part of the activity and claim 0.5 credits(s). I participated in only part of the activity and claim 0.25 credits(s). Question Title * 20. Contact information Name Degree State/Province Email Address Done